RBR-107j3g4v进行中（未招募）3 期
Cholinergic stimulation with Pyridostigmine bromide in the treatment of fatigue secondary to SARS-Cov2 infection
niversidade Federal Fluminense0 个研究点开始时间: 2023年8月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18Y 至 65Y（—）
入选标准
- •Individuals with a recent history of SARS Cov2 infection, confirmed by positive PCR; age between 18 and 65 years; patients who maintain permanent symptoms, mainly fatigue, after 4 weeks of the onset of the illness
排除标准
- •Individuals with some type of motor or mental disability that prevents the performance of the proposed tests; pregnant women; subjects with known hypersensitivity to pyridostigmine; individuals with conditions that contraindicate the use of pyridostigmine, such as glaucoma, asthma and urinary obstruction; patients with heart rhythm different from sinus rhythm, with atrial fibrillation, frequent ventricular and/or supraventricular ectopy
研究者
相似试验
已完成
2 期
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1pijn syndroomdystrophypost-traumatic dystrophyreflex sympathetic dystrophyNL-OMON33787Vrije Universiteit Medisch Centrum10
进行中（未招募）
不适用
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1 - Pyridostigmine trialPatients with CRPS-1.EUCTR2009-010758-36-NLVU University Medical Center10
尚未招募
不适用
The effect of Pyridostigmine on patients with CRPS-1.complex regional pain syndrome, neuropathic pain, neurogenic inflammation,NL-OMON20521TREND10
招募中
1 期
Improving symptomatic treatment with pyridostigmine and amifampridine in patients with myasthenia gravisMedDRA version: 24.0Level: LLTClassification code 10085562Term: AChR myasthenia gravisSystem Organ Class: 100000004852Myasthenia GravisEUCTR2021-004110-20-NLeiden University Medical Center24
招募中
3 期
Improving symptomatic treatment with pyridostigmine and amifampridine: a randomized double-blinded, placebo controlled crossover trial in patients with myasthenia gravis (IMPACT-MG)Myasthenia GravisNL-OMON54093eids Universitair Medisch Centrum24